Minimize Toxicity or Preserve Efficacy? A Delicate Trade-Off in the Management of Older Patients With Lung Cancer
Mené sur 276 patients atteints d'un cancer avancé du poumon non à petites cellules (âge médian : 76 ans), cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de cisplatine au docétaxel
Lung cancer is a disease of older patients in large part because of the long latency between tobacco carcinogen exposure and the development of lung cancer. Non–tobacco-related lung cancer mortality also increases with age. The majority of the patients with lung cancer in the United States are diagnosed in the seventh decade of life, and approximately 14% of elderly patients with lung cancer are in fact 80 years of age or older...